Drug interactions with lipid‐lowering drugs: Mechanisms and clinical relevance
暂无分享,去创建一个
[1] P. Reaven,et al. Lovastatin, nicotinic acid, and rhabdomyolysis. , 1988, Annals of internal medicine.
[2] J. Tobert. Efficacy and long-term adverse effect pattern of lovastatin. , 1988, The American journal of cardiology.
[3] S. Grundy,et al. Rhabdomyolysis in patients receiving lovastatin after cardiac transplantation. , 1988, The New England journal of medicine.
[4] J. Derancourt,et al. Metabolism of cyclosporin A. IV. Purification and identification of the rifampicin-inducible human liver cytochrome P-450 (cyclosporin A oxidase) as a product of P450IIIA gene subfamily. , 1989, Drug metabolism and disposition: the biological fate of chemicals.
[5] K. K. Larson,et al. Rhabdomyolysis and acute renal failure induced by combination lovastatin and gemfibrozil therapy. , 1990, Annals of internal medicine.
[6] K. Hasegawa,et al. Tissue-selective inhibition of cholesterol synthesis in vivo by pravastatin sodium, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. , 1990, Biochimica et biophysica acta.
[7] D. Spach,et al. Rhabdomyolysis associated with lovastatin and erythromycin use. , 1991, The Western journal of medicine.
[8] A. Y. Lu,et al. Biotransformation of lovastatin. IV. Identification of cytochrome P450 3A proteins as the major enzymes responsible for the oxidative metabolism of lovastatin in rat and human liver microsomes. , 1991, Archives of biochemistry and biophysics.
[9] A. Gavazzi,et al. Altered disposition of pravastatin following concomitant drug therapy with cyclosporin A in transplant recipients. , 1993, Transplantation proceedings.
[10] J. D. Karkas,et al. Plasma concentration profiles of simvastatin 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase inhibitory activity in kidney transplant recipients with and without ciclosporin. , 1993, Nephron.
[11] C. Sirtori,et al. Tissue selectivity of hydroxymethylglutaryl coenzyme A (HMG CoA) reductase inhibitors. , 1993, Pharmacology & therapeutics.
[12] Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) , 1994, The Lancet.
[13] G. A. Scarborough,et al. Direct demonstration of high affinity interactions of immunosuppressant drugs with the drug binding site of the human P-glycoprotein. , 1994, Molecular pharmacology.
[14] Lisa Anne Hendricks,et al. Pharmacokinetics of the combination of fluvastatin and gemfibrozil. , 1995, The American journal of cardiology.
[15] R. Lees,et al. Rhabdomyolysis from the coadministration of lovastatin and the antifungal agent itraconazole. , 1995, The New England journal of medicine.
[16] P. Neuvonen,et al. Itraconazole drastically increases plasma concentrations of lovastatin and lovastatin acid , 1996, Clinical pharmacology and therapeutics.
[17] G. Schectman,et al. Dose-Response Characteristics of Cholesterol-Lowering Drug Therapies: Implications for Treatment , 1996, Annals of Internal Medicine.
[18] T. Leemann,et al. In vitro comparative inhibition profiles of major human drug metabolising cytochrome P450 isozymes (CYP2C9, CYP2D6 and CYP3A4) by HMG-CoA reductase inhibitors , 1996, European Journal of Clinical Pharmacology.
[19] C. Glueck,et al. Myositis and rhabdomyolysis associated with concurrent use of simvastatin and nefazodone. , 1997, JAMA.
[20] U. Christians,et al. Accumulation of lovastatin, but not pravastatin, in the blood of cyclosporine‐treated kidney graft patients after multiple doses , 1997, Clinical pharmacology and therapeutics.
[21] H. Lennernäs,et al. Pharmacodynamics and Pharmacokinetics of the HMG-CoA Reductase Inhibitors , 1997, Clinical pharmacokinetics.
[22] B H Arison,et al. In vitro metabolism of simvastatin in humans [SBT]identification of metabolizing enzymes and effect of the drug on hepatic P450s. , 1997, Drug metabolism and disposition: the biological fate of chemicals.
[23] P. Neuvonen,et al. Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole , 1998, Clinical pharmacology and therapeutics.
[24] W. Haefeli,et al. Rhabdomyolysis due to interaction of simvastatin with mibefradil , 1998, The Lancet.
[25] P. Neuvonen,et al. Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid , 1998, Clinical pharmacology and therapeutics.
[26] K. Ochmann,et al. PHARMACOKINETICS AND DISPOSITION , 1998 .
[27] S. Hall,et al. The interaction of diltiazem with lovastatin and pravastatin , 1998, Clinical pharmacology and therapeutics.
[28] P. Neuvonen,et al. Different effects of itraconazole on the pharmacokinetics of fluvastatin and lovastatin. , 1998, British journal of clinical pharmacology.
[29] U. Christians,et al. Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in transplant patients: are the statins mechanistically similar? , 1998, Pharmacology & therapeutics.
[30] S. Olson,et al. Atorvastatin does not Produce a Clinically Significant Effect on the Pharmacokinetics of Terfenadine , 1998, Journal of clinical pharmacology.
[31] P. Neuvonen,et al. Erythromycin and verapamil considerably increase serum simvastatin and simvastatin acid concentrations , 1998, Clinical pharmacology and therapeutics.
[32] J. Turgeon,et al. Hydrophilicity/lipophilicity: relevance for the pharmacology and clinical effects of HMG-CoA reductase inhibitors. , 1998, Trends in pharmacological sciences.
[33] P. Neuvonen,et al. Grapefruit juice—simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG‐CoA reductase inhibitors , 1998, Clinical pharmacology and therapeutics.
[34] P. Neuvonen,et al. Effect of itraconazole on the pharmacokinetics of atorvastatin , 1998, Clinical pharmacology and therapeutics.
[35] L Fritsche,et al. Increase in cerivastatin systemic exposure after single and multiple dosing in cyclosporine‐treated kidney transplant recipients , 1999, Clinical pharmacology and therapeutics.
[36] P. Neuvonen,et al. PHARMACOKINETICS AND DISPOSITION , 1999 .
[37] M. Dominiczak,et al. Efficacy of statin therapy: possible effect of phenytoin , 1999, Postgraduate medical journal.
[38] L. Ramsay,et al. Enhanced cholesterol reduction by simvastatin in diltiazem-treated patients. , 1999, British journal of clinical pharmacology.
[39] Jamie J. Zhao,et al. Grapefruit juice has minimal effects on plasma concentrations of lovastatin‐derived 3‐hydroxy‐3‐methylglutaryl coenzyme A reductase inhibitors , 1999, Clinical pharmacology and therapeutics.
[40] P. Neuvonen,et al. Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin , 1999, Clinical pharmacology and therapeutics.
[41] T. Uchiumi,et al. Effect of multidrug resistance-reversing agents on transporting activity of human canalicular multispecific organic anion transporter. , 1999, Molecular pharmacology.
[42] S. Olson,et al. Erythromycin Coadministration Increases Plasma Atorvastatin Concentrations , 1999, Journal of clinical pharmacology.
[43] S. Hall,et al. The interaction of diltiazem with simvastatin , 2000, Clinical pharmacology and therapeutics.
[44] P. Neuvonen,et al. Duration of effect of grapefruit juice on the pharmacokinetics of the CYP3A4 substrate simvastatin , 2000, Clinical pharmacology and therapeutics.
[45] M. Rieser,et al. Lack of a Clinically Significant Pharmacokinetic Interaction between Fenofibrate and Pravastatin in Healthy Volunteers , 2000, Journal of clinical pharmacology.
[46] A. Mazzu,et al. Itraconazole alters the pharmacokinetics of atorvastatin to a greater extent than either cerivastatin or pravastatin , 2000, Clinical pharmacology and therapeutics.
[47] P. Neuvonen,et al. Plasma concentrations of active simvastatin acid are increased by gemfibrozil , 2000, Clinical pharmacology and therapeutics.
[48] R. Davidson,et al. Selectivity of ZD4522 for inhibition of cholesterol synthesis in hepatic versus non-hepatic cells , 2000 .
[49] P. Neuvonen,et al. Effect of fluconazole on plasma fluvastatin and pravastatin concentrations , 2000, European Journal of Clinical Pharmacology.
[50] W. Mück. Clinical Pharmacokinetics of Cerivastatin , 2000, Clinical pharmacokinetics.
[51] P. Kollman,et al. Lactonization is the critical first step in the disposition of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor atorvastatin. , 2000, Drug metabolism and disposition: the biological fate of chemicals.
[52] B. H. Stewart,et al. Atorvastatin Coadministration May Increase Digoxin Concentrations by Inhibition of Intestinal P‐Glycoprotein‐Mediated Secretion , 2000, Journal of clinical pharmacology.
[53] P. Neuvonen,et al. Rifampin greatly reduces plasma simvastatin and simvastatin acid concentrations , 2000, Clinical pharmacology and therapeutics.
[54] P. Neuvonen,et al. Effect of gemfibrozil on the pharmacokinetics and pharmacodynamics of glimepiride , 2001, Clinical pharmacology and therapeutics.
[55] N. Ichimaru,et al. Changes in lipid metabolism and effect of simvastatin in renal transplant recipients induced by cyclosporine or tacrolimus. , 2001, Atherosclerosis.
[56] Y. Sugiyama,et al. A comparison of the effects of 3-hydroxy-3-methylglutaryl-coenzyme a (HMG-CoA) reductase inhibitors on the CYP3A4-dependent oxidation of mexazolam in vitro. , 2001, Drug metabolism and disposition: the biological fate of chemicals.
[57] C. Scripture,et al. Clinical Pharmacokinetics of Fluvastatin , 2001, Clinical pharmacokinetics.
[58] M. Ito,et al. Colesevelam Hydrochloride: A Novel Bile Acid-Binding Resin , 2001, The Annals of pharmacotherapy.
[59] A. Hartmann,et al. Bilateral Pharmacokinetic Interaction Between Cyclosporine A and Atorvastatin in Renal Transplant Recipients , 2001, American Journal of Transplantation.
[60] W. Jaross,et al. Pharmacokinetics and Pharmacodynamics of Fluvastatin in Heart Transplant Recipients Taking Cyclosporine A , 2001, Journal of cardiovascular pharmacology and therapeutics.
[61] J. S. Wang,et al. Gemfibrozil is a potent inhibitor of human cytochrome P450 2C9. , 2001, Drug metabolism and disposition: the biological fate of chemicals.
[62] James P. Wilson,et al. Rhabdomyolysis and HMG-CoA Reductase Inhibitors , 2001, The Annals of pharmacotherapy.
[63] P. Neuvonen,et al. Plasma concentrations of active lovastatin acid are markedly increased by gemfibrozil but not by bezafibrate , 2001, Clinical pharmacology and therapeutics.
[64] T. Abe,et al. Human liver-specific organic anion transporter, LST-1, mediates uptake of pravastatin by human hepatocytes. , 2001, The Journal of pharmacology and experimental therapeutics.
[65] A. Dane,et al. The effect of fluconazole on the pharmacokinetics of rosuvastatin , 2002, European Journal of Clinical Pharmacology.
[66] C. Fichtenbaum,et al. Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047 , 2002, AIDS.
[67] P. Neuvonen,et al. Gemfibrozil inhibits CYP2C8-mediated cerivastatin metabolism in human liver microsomes. , 2002, Drug metabolism and disposition: the biological fate of chemicals.
[68] James P. Wilson,et al. FDA Adverse Event Reports on Statin-Associated Rhabdomyolysis , 2002, The Annals of pharmacotherapy.
[69] A. Manginas,et al. Itraconazole-induced rhabdomyolysis and acute renal failure in a heart transplant recipient treated with simvastatin and cyclosporine , 2002, Transplantation.
[70] J. Feely,et al. Pharmacokinetic-Pharmacodynamic Drug Interactions with HMG-CoA Reductase Inhibitors , 2002, Clinical pharmacokinetics.
[71] G. Amsden,et al. A Study of the Interaction Potential of Azithromycin and Clarithromycin with Atorvastatin in Healthy Volunteers , 2002, Journal of clinical pharmacology.
[72] R. Subramanian,et al. Effects of fibrates on metabolism of statins in human hepatocytes. , 2002, Drug metabolism and disposition: the biological fate of chemicals.
[73] Jennie Chang,et al. Cerivastatin and reports of fatal rhabdomyolysis. , 2002, The New England journal of medicine.
[74] B. Ma,et al. Glucuronidation of statins in animals and humans: a novel mechanism of statin lactonization. , 2002, Drug metabolism and disposition: the biological fate of chemicals.
[75] B. Ma,et al. Mechanistic studies on metabolic interactions between gemfibrozil and statins. , 2002, The Journal of pharmacology and experimental therapeutics.
[76] P. Neuvonen,et al. Gemfibrozil greatly increases plasma concentrations of cerivastatin , 2002, Clinical pharmacology and therapeutics.
[77] J. Lewin,et al. Rhabdomyolysis with Concurrent Atorvastatin and Diltiazem , 2002, The Annals of pharmacotherapy.
[78] W. März,et al. Risk for myopathy with statin therapy in high-risk patients. , 2003, Archives of internal medicine.
[79] P. Neuvonen,et al. Gemfibrozil considerably increases the plasma concentrations of rosiglitazone , 2003, Diabetologia.
[80] Paul D. Martin,et al. The effect of erythromycin on the pharmacokinetics of rosuvastatin , 2003, European Journal of Clinical Pharmacology.
[81] G. Shorten,et al. The effects of concurrent atorvastatin therapy on the pharmacokinetics of intravenous midazolam , 2003, Anaesthesia.
[82] Paul D. Martin,et al. Effect of itraconazole on the pharmacokinetics of rosuvastatin , 2003, Clinical pharmacology and therapeutics.
[83] Paul D. Martin,et al. An open-label, randomized, three-way crossover trial of the effects of coadministration of rosuvastatin and fenofibrate on the pharmacokinetic properties of rosuvastatin and fenofibric acid in healthy male volunteers. , 2003, Clinical therapeutics.
[84] A. Åsberg. Interactions between cyclosporin and lipid-lowering drugs: implications for organ transplant recipients. , 2003, Drugs.
[85] P. Neuvonen,et al. Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics and pharmacodynamics of repaglinide: potentially hazardous interaction between gemfibrozil and repaglinide , 2003, Diabetologia.
[86] B. Ma,et al. The human hepatic metabolism of simvastatin hydroxy acid is mediated primarily by CYP3A, and not CYP2D6. , 2003, British journal of clinical pharmacology.
[87] P. Neuvonen,et al. Carbamazepine markedly reduces serum concentrations of simvastatin and simvastatin acid , 2004, European Journal of Clinical Pharmacology.
[88] P. Neuvonen,et al. Gemfibrozil increases plasma pravastatin concentrations and reduces pravastatin renal clearance , 2003, Clinical pharmacology and therapeutics.
[89] Potential drug interaction between simvastatin and danazol causing rhabdomyolysis. , 2003, The Canadian journal of clinical pharmacology = Journal canadien de pharmacologie clinique.
[90] Paul B. Watkins,et al. Atorvastatin Reduces the Ability of Clopidogrel to Inhibit Platelet Aggregation: A New Drug–Drug Interaction , 2003, Circulation.
[91] L. Waskell,et al. The metabolism of clopidogrel is catalyzed by human cytochrome P450 3A and is inhibited by atorvastatin. , 2003, Drug metabolism and disposition: the biological fate of chemicals.
[92] Yuichi Sugiyama,et al. Inhibition of Transporter-Mediated Hepatic Uptake as a Mechanism for Drug-Drug Interaction between Cerivastatin and Cyclosporin A , 2003, Journal of Pharmacology and Experimental Therapeutics.
[93] Yuichi Sugiyama,et al. Polymorphisms of OATP‐C (SLC21A6) and OAT3 (SLC22A8) genes: Consequences for pravastatin pharmacokinetics , 2003, Clinical pharmacology and therapeutics.
[94] M. Affrime,et al. Assessment of a multiple-dose drug interaction between ezetimibe, a novel selective cholesterol absorption inhibitor and gemfibrozil. , 2004, International journal of clinical pharmacology and therapeutics.
[95] Miranda R Andrus,et al. Oral Anticoagulant Drug Interactions with Statins: Case Report of Fluvastatin and Review of the Literature , 2004, Pharmacotherapy.
[96] R. Schlienger,et al. Rhabdomyolysis in Association with Simvastatin and Amiodarone , 2004, The Annals of pharmacotherapy.
[97] Richard Platt,et al. Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. , 2004, JAMA.
[98] Steffen Bauer,et al. Evidence for Inverse Effects of OATP‐C (SLC21A6) *5 and *1b Haplotypes on Pravastatin Kinetics , 2004, Clinical pharmacology and therapeutics.
[99] G. Dresser,et al. Interactions Between Grapefruit Juice and Cardiovascular Drugs , 2004, American journal of cardiovascular drugs : drugs, devices, and other interventions.
[100] P. Neuvonen,et al. Lack of effect of bezafibrate and fenofibrate on the pharmacokinetics and pharmacodynamics of repaglinide. , 2004, British journal of clinical pharmacology.
[101] P. Pentikäinen,et al. Rhabdomyolysis associated with concomitant use of simvastatin and clarithromycin , 2004, The Annals of pharmacotherapy.
[102] M. Eisenberg,et al. Rhabdomyolysis associated with hydroxymethylglutaryl-coenzyme A reductase inhibitors☆ , 2004 .
[103] P. Neuvonen,et al. High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1). , 2004, Pharmacogenetics.
[104] Helen Pilmore,et al. Potentially fatal interaction between diltiazem and statins. , 2004, Annals of internal medicine.
[105] Paul D. Martin,et al. The effect of gemfibrozil on the pharmacokinetics of rosuvastatin , 2004, Clinical pharmacology and therapeutics.
[106] J. Paolini,et al. Simvastatin Does Not Have a Clinically Significant Pharmacokinetic Interaction With Fenofibrate in Humans , 2004, Journal of clinical pharmacology.
[107] P. Neuvonen,et al. Pharmacokinetics and Pharmacodynamics of Pravastatin in Pediatric and Adolescent Cardiac Transplant Recipients on a Regimen of Triple Immunosuppression , 2004, Clinical pharmacology and therapeutics.
[108] U. Hofmann,et al. Characterisation of cerivastatin as a P-glycoprotein substrate: studies in P-glycoprotein-expressing cell monolayers and mdr1a/b knock-out mice , 2004, Naunyn-Schmiedeberg's Archives of Pharmacology.
[109] Y. Sugiyama,et al. Gemfibrozil and Its Glucuronide Inhibit the Organic Anion Transporting Polypeptide 2 (OATP2/OATP1B1:SLC21A6)-Mediated Hepatic Uptake and CYP2C8-Mediated Metabolism of Cerivastatin: Analysis of the Mechanism of the Clinically Relevant Drug-Drug Interaction between Cerivastatin and Gemfibrozil , 2004, Journal of Pharmacology and Experimental Therapeutics.
[110] H. Yamada,et al. Pharmacokinetic and pharmacodynamic interactions between simvastatin and diltiazem in patients with hypercholesterolemia and hypertension. , 2004, Life sciences.
[111] Eiji Uchida,et al. Effects of grapefruit juice on pharmacokinetics of atorvastatin and pravastatin in Japanese. , 2004, British journal of clinical pharmacology.
[112] P. Neuvonen,et al. Effects of regular consumption of grapefruit juice on the pharmacokinetics of simvastatin. , 2004, British journal of clinical pharmacology.
[113] A. Åsberg,et al. Substantially elevated levels of atorvastatin and metabolites in cyclosporine‐treated renal transplant recipients , 2004, Clinical pharmacology and therapeutics.
[114] M. Eisenberg,et al. Rhabdomyolysis associated with hydroxymethylglutaryl-coenzyme A reductase inhibitors. , 2004, American heart journal.
[115] T. Sakaeda,et al. Metabolic properties of the acid and lactone forms of HMG-CoA reductase inhibitors , 2004, Xenobiotica; the fate of foreign compounds in biological systems.
[116] M. Endres,et al. Statin-associated rhabdomyolysis triggered by grapefruit consumption , 2004, Neurology.
[117] R. Kim,et al. 3‐Hydroxy‐3‐methylglutaryl–coenzyme a Reductase Inhibitors (statins) and Genetic Variability (Single Nucleotide Polymorphisms) in a Hepatic Drug Uptake Transporter: What's it all About? , 2004, Clinical pharmacology and therapeutics.
[118] P. Neuvonen,et al. Effect of rifampicin on pravastatin pharmacokinetics in healthy subjects. , 2003, British journal of clinical pharmacology.
[119] E. Wang,et al. HMG-CoA Reductase Inhibitors (Statins) Characterized as Direct Inhibitors of P-Glycoprotein , 2001, Pharmaceutical Research.
[120] Paul D. Martin,et al. Rosuvastatin pharmacokinetics in heart transplant recipients administered an antirejection regimen including cyclosporine , 2004, Clinical pharmacology and therapeutics.
[121] T. Cuddy,et al. An open‐label study on the pharmacokinetics (PK) of pitavastatin (NK‐104) when administered concomitantly with fenofibrate or gemfibrozil in healthy volunteers , 2004 .
[122] J. Slattery,et al. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). 1994. , 1994, Atherosclerosis. Supplements.
[123] K. Kivistö,et al. Rhabdomyolysis in a patient receiving atorvastatin and fluconazole , 2005, European Journal of Clinical Pharmacology.
[124] H. Kusuhara,et al. Effect of genetic polymorphism of OATP-C (SLCO1B1) on lipid-lowering response to HMG-CoA reductase inhibitors. , 2004, Drug metabolism and pharmacokinetics.
[125] Mikko Niemi,et al. Polymorphic Organic Anion Transporting Polypeptide 1B1 is a Major Determinant of Repaglinide Pharmacokinetics , 2005, Clinical pharmacology and therapeutics.
[126] P. Neuvonen,et al. Effects of Gemfibrozil, Itraconazole, and Their Combination on the Pharmacokinetics of Pioglitazone , 2005, Clinical pharmacology and therapeutics.
[127] P. Neuvonen,et al. Coadministration of gemfibrozil and itraconazole has only a minor effect on the pharmacokinetics of the CYP2C9 and CYP3A4 substrate nateglinide. , 2005, British journal of clinical pharmacology.
[128] P. Neuvonen,et al. Cyclosporine markedly raises the plasma concentrations of repaglinide , 2005, Clinical pharmacology and therapeutics.
[129] R. Tirona. Ethnic differences in statin disposition , 2005, Clinical pharmacology and therapeutics.
[130] Michael Schachter,et al. Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update , 2005, Fundamental & clinical pharmacology.
[131] T. Sakaeda,et al. Effects of Acid and Lactone Forms of Eight HMG-CoA Reductase Inhibitors on CYP-Mediated Metabolism and MDR1-Mediated Transport , 2005, Pharmaceutical Research.
[132] J. Xu,et al. DIFFERENTIAL INTERACTION OF 3-HYDROXY-3-METHYLGLUTARYL-COA REDUCTASE INHIBITORS WITH ABCB1, ABCC2, AND OATP1B1 , 2005, Drug Metabolism and Disposition.
[133] P. Neuvonen,et al. Effect of gemfibrozil on the pharmacokinetics and pharmacodynamics of racemic warfarin in healthy subjects. , 2005, British journal of clinical pharmacology.
[134] G. Miller,et al. Drug therapy in the heart transplant recipient: part IV: drug-drug interactions. , 2005, Circulation.
[135] Caroline A. Lee,et al. Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment , 2005, Clinical pharmacology and therapeutics.
[136] Kazuya Maeda,et al. Identification of the Hepatic Efflux Transporters of Organic Anions Using Double-Transfected Madin-Darby Canine Kidney II Cells Expressing Human Organic Anion-Transporting Polypeptide 1B1 (OATP1B1)/Multidrug Resistance-Associated Protein 2, OATP1B1/Multidrug Resistance 1, and OATP1B1/Breast Cancer R , 2005, Journal of Pharmacology and Experimental Therapeutics.
[137] P. Neuvonen,et al. Comparison of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) as inhibitors of cytochrome P450 2C8. , 2005, Basic & clinical pharmacology & toxicology.
[138] P. Neuvonen,et al. Rifampin markedly decreases and gemfibrozil increases the plasma concentrations of atorvastatin and its metabolites , 2005, Clinical pharmacology and therapeutics.
[139] J. Paolini,et al. Ezetimibe , 2005, Clinical pharmacokinetics.
[140] Y Vanrenterghem,et al. Combined Therapy with Atorvastatin and Calcineurin Inhibitors: No Interactions with Tacrolimus , 2005, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[141] D. Oh,et al. Effect of OATP1B1 (SLCO1B1) variant alleles on the pharmacokinetics of pitavastatin in healthy volunteers , 2005, Clinical pharmacology and therapeutics.
[142] E. Wolfel,et al. Drug therapy in the heart transplant recipient: Part III: common medical problems. , 2005, Circulation.
[143] U. Hofmann,et al. Acute effects of pravastatin on cholesterol synthesis are associated with SLCO1B1 (encoding OATP1B1) haplotype *17 , 2005, Pharmacogenetics and genomics.
[144] R. Kim,et al. Transporters and drug therapy: Implications for drug disposition and disease , 2005, Clinical pharmacology and therapeutics.
[145] S. Kaneko,et al. Effects of grapefruit juice on the pharmacokinetics of pitavastatin and atorvastatin. , 2005, British journal of clinical pharmacology.
[146] K. Maeda,et al. Bile Salt Export Pump (BSEP/ABCB11) Can Transport a Nonbile Acid Substrate, Pravastatin , 2005, Journal of Pharmacology and Experimental Therapeutics.
[147] Yuichi Sugiyama,et al. Evaluation of drug-drug interaction in the hepatobiliary and renal transport of drugs. , 2005, Annual review of pharmacology and toxicology.
[148] M. Davidson,et al. Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin. , 2005, The American journal of cardiology.
[149] D. Keppler,et al. Human Hepatobiliary Transport of Organic Anions Analyzed by Quadruple-Transfected Cells , 2005, Molecular Pharmacology.
[150] Paul D. Martin,et al. Effect of Rosuvastatin on Warfarin Pharmacodynamics and Pharmacokinetics , 2005, Journal of clinical pharmacology.
[151] P. Poirier,et al. Ezetimibe-associated myopathy in monotherapy and in combination with a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. , 2006, The Canadian journal of cardiology.
[152] J. Paolini,et al. Interaction of Single‐Dose Ezetimibe and Steady‐State Cyclosporine in Renal Transplant Patients , 2006, Journal of clinical pharmacology.
[153] A. D. Rodrigues,et al. GLUCURONIDATION CONVERTS GEMFIBROZIL TO A POTENT, METABOLISM-DEPENDENT INHIBITOR OF CYP2C8: IMPLICATIONS FOR DRUG-DRUG INTERACTIONS , 2006, Drug Metabolism and Disposition.
[154] P. Neuvonen,et al. Association of genetic polymorphism in ABCC2 with hepatic multidrug resistance-associated protein 2 expression and pravastatin pharmacokinetics , 2006, Pharmacogenetics and genomics.
[155] T. Edeki,et al. Evaluation of the potential for pharmacokinetic interaction between fenofibrate and ezetimibe: A phase I, open-label, multiple-dose, three-period crossover study in healthy subjects. , 2006, Clinical therapeutics.
[156] J. Paolini,et al. Effects of Ezetimibe on Cyclosporine Pharmacokinetics in Healthy Subjects , 2006, Journal of clinical pharmacology.
[157] P. Neuvonen,et al. The CYP2C8 inhibitor gemfibrozil does not increase the plasma concentrations of zopiclone , 2006, European Journal of Clinical Pharmacology.
[158] R. Kim,et al. Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and pharmacogenetics. , 2006, Gastroenterology.
[159] Alicja R Rudnicka,et al. Statin safety: a systematic review. , 2006, The American journal of cardiology.
[160] K. Maeda,et al. DRUG-DRUG INTERACTION BETWEEN PITAVASTATIN AND VARIOUS DRUGS VIA OATP1B1 , 2006, Drug Metabolism and Disposition.
[161] P. Neuvonen,et al. SLCO1B1 polymorphism and sex affect the pharmacokinetics of pravastatin but not fluvastatin , 2006, Clinical pharmacology and therapeutics.
[162] Yuichi Sugiyama,et al. Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions. , 2006, Pharmacology & therapeutics.
[163] P. Neuvonen,et al. Itraconazole, gemfibrozil and their combination markedly raise the plasma concentrations of loperamide , 2006, European Journal of Clinical Pharmacology.
[164] Mikko Niemi,et al. SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid , 2006, Pharmacogenetics and genomics.
[165] H. Bays. Statin safety: an overview and assessment of the data--2005. , 2006, The American journal of cardiology.